Skip to content

Clinical trials

Phase 2 Multiple Sclerosis, Relapsing-Remitting trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Multiple Sclerosis, Relapsing-Remitting Phase: Phase 2 Country / region: United States Clear all

40 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20023
20032
20042
20062
20072
20081
20092
20105
20112
20132
20143
20152
20171
20182
20191
20212
20221
20231
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed23
Terminated7
Unknown status4
Withdrawn3
Suspended1
Not yet recruiting1
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novartis Pharmaceuticals4
Biogen3
Genzyme, a Sanofi Company3
Eli Lilly and Company2
Genentech, Inc.2
National Institute of Allergy and Infectious Diseases (NIAID)2
Opexa Therapeutics, Inc.2
University of California, Los Angeles2
Bayer1
Beijing InnoCare Pharma Tech Co., Ltd.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Multiple Sclerosis, Relapsing-Remitting40
Multiple Sclerosis23
Demyelinating Diseases3
Multiple Sclerosis, Chronic Progressive3
Recurrence2
Autoimmune Diseases of the Nervous System1
Diffuse Cerebral Sclerosis of Schilder1
Disease Progression1
Fatigue1
Nervous System Diseases1

Trials

Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.